Φορτώνει......
European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
Xeljanz(®) (tofacitinib) is an oral small-molecule inhibitor that reversibly inhibits Janus-activated kinase (JAK)-dependent cytokine signaling, thus reducing inflammation. As a result of these mechanisms, effects on the immune system such as a moderate decrease in the total lymphocyte count, a dose...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Ther Clin Risk Manag |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5743127/ https://ncbi.nlm.nih.gov/pubmed/29317823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S138677 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|